Menu

1 / 2

Novo Nordisk: A Return To Growth May Be Just Around The Corner

All Articles on Seeking Alpha·about 20 hours ago
#LW9k97K6
#seekingalpha#stock#seeking#alpha#investors
Long article (288 words) — no AI summary yet.
Reading 0:00
15s threshold

Home

Stock Ideas

Long Ideas

Healthcare

Summary

I maintain a Buy on Novo Nordisk A/S: a 10–11 forward P/E looks inexpensive given potential returning to growth.

Two quarterly beats and raised guidance support modest NVO 2026 growth; stronger-than-expected 2027 guidance could help NVO regain momentum.

I see CagriSema approval and a successful launch as critical to NVO closing the efficacy gap with Lilly and establishing an amylin first-mover advantage.

Patent losses, China headwinds and intensifying competition remain risks, but Wegovy pill uptake and new launches could support an upside surprise.

aprott/iStock via Getty Images

Intro

I believe many investors are wondering what it will take for Novo Nordisk A/S's ( NVO ) stock to finally find its footing and begin a sustained recovery.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.